Heidelberg Pharma GmbH

36 articles about Heidelberg Pharma GmbH

• Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2018

  11/2/2018

  - Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation

• The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend Their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy

  10/18/2018

  In recent years, checkpoint inhibitors have changed treatment paradigms in cancer.

• Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate

  10/15/2018

  Heidelberg Pharma AG today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, exercises its option to further develop a target molecule, and will now continue the development of an Antibody Targeted Amanitin Conjugate based on the target molecule within an exclusive licensing.

• Heidelberg Pharma AG: Interim management statement on the first nine months of 2018

  10/11/2018

  Key milestones reached for GMP manufacturing of HDP-101

• Heidelberg Pharma AG: Partner Telix Pharmaceuticals Files Phase III Trial for Kidney Cancer Imaging in Europe

  8/23/2018

  Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that its partner Telix Pharmaceuticals Limited ("Telix") (ASX:TLX), has submitted a Clinical Trial Application (CTA) to initiate a Phase III trial in Europe for 89Zr-DFO-girentuximab (TLX250) for the imaging of renal (kidney) cancer with Positron Emission Tomography (PET).

• 

  Magenta Therapeutics Snags $52 Million to Advance Bone Marrow Transplant Medications

  4/9/2018

  Fresh off of striking a research deal with Ladenburg, Germany-based Heidelberg Pharma GmbH, Magenta Therapeutics secured $52 million.The funds will be used to advance Magenta's portfolio of bone marrow transplant medications.
• 

  Magenta Therapeutics and Heidelberg Pharma Team Up for Bone Marrow Transplants

  3/6/2018

  Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma to improve curative bone marrow transplantation.

• Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates

  3/5/2018

  Collaboration enables and accelerates Magenta’s research and development efforts across several targeted conditioning programs for bone marrow transplant; Expands application of Heidelberg Pharma ATAC technology to new targets

• Heidelberg Pharma AG and Advanced Proteome Therapeutics Progress Collaborative Program

  1/9/2018

  The companies have agreed to test the combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate superior cancer therapeutics.

• Heidelberg Pharma AG Announces Results From Research Collaboration With Heidelberg University and the DKFZ to be Presented at ASH Annual Meeting

  11/13/2017

  The collaboration evaluated the efficacy of the development candidate HDP-101 on multiple myeloma cells isolated from patients. HDP-101 consists of a BCMA antibody, a specific linker and the toxin Amanitin.

• Heidelberg Pharma AG Plans Capital Measure to Fund Its ATAC Development Programs

  11/3/2017

  The funding measure will consist of a capital increase from authorized capital and from the issue of convertible bonds.

• Wilex AG: Subsidiary Heidelberg Pharma Becomes Runner Up In The Category Best New Drug Developer At World ADC Award 2017

  9/26/2017

• Wilex AG: Subsidiary Heidelberg Pharma To Present The Proprietary ATAC Technology Platform At The Annual World ADC Summit

  9/20/2017

• Wilex AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-Target Research Agreement With Takeda For The Development Of Antibody Targeted Amanitin Conjugates

  6/20/2017

• Nordic Nanovector And Heidelberg Pharma Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCs) Targeting Leukaemias

  10/26/2016

• MDC And Heidelberg Pharma To Collaborate On Novel Cancer Treatment

  9/19/2016